Markets:

Overview

News

Currencies

International

Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

13.93 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer.

Via The Motley Fool

Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗

March 16, 2026

Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead candidate in clinical trials for breast cancer treatment.

Via The Motley Fool

Topics Regulatory Compliance

Olema Pharmaceuticals Inc (NASDAQ:OLMA) Beats Q4 2025 EPS Estimates, Provides Key Pipeline Updates ↗

March 16, 2026

Via Chartmill

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗

March 15, 2026

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Via The Motley Fool

Top stock movements in today's session. ↗

March 09, 2026

Via Chartmill

Monday's session: top gainers and losers ↗

March 09, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 09, 2026

Via Chartmill

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading...

Via Benzinga

Topics Stocks

Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗

February 25, 2026

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

Via The Motley Fool

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗

February 25, 2026

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗

February 25, 2026

Disc Medicine develops therapies for rare blood disorders, leveraging clinical-stage biotech expertise in red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

Olema Insider Sells $8 Million in Shares After 300% Stock Surge ↗

January 09, 2026

Focused on therapies for women's cancers, this clinical-stage biotech reported a significant insider sale amid a year of sharp stock gains.

Via The Motley Fool

Topics Regulatory Compliance

In today's session, these stocks are experiencing unusual volume. ↗

November 20, 2025

On Thursday, there are stocks with unusual volume. Let's take a look.

Via Chartmill

Keep an eye on the top gainers and losers in Thursday's session. ↗

November 20, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 20, 2025

Via Benzinga

Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million ↗

November 20, 2025

Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday ↗

November 20, 2025

Via Benzinga

Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer ↗

November 20, 2025

Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way

Via The Motley Fool

Topics Regulatory Compliance

In today's session, these stocks are experiencing unusual volume. ↗

November 19, 2025

Let's explore the current happenings on the US markets on Wednesday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Via Chartmill

Biotech Stock Gets Booted in Latest Fund Update ↗

November 19, 2025

Bain Capital sold its entire stake in Nuvalent stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock ↗

November 19, 2025

Bain Capital completely exited its position in Disc Medicine stock during the third quarter

Via The Motley Fool

Which stocks are moving on Tuesday? ↗

November 18, 2025

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Via Chartmill

Which stocks are most active on Tuesday? ↗

November 18, 2025

Discover the most active stocks in Tuesday's session. Stay informed about the stocks that are generating the most trading volume!

Via Chartmill

Why Bain Capital Is Selling Shares of This Biotech Stock Now ↗

November 18, 2025

Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.

Via The Motley Fool

Topics Regulatory Compliance

Top movers in Tuesday's session ↗

November 18, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock ↗

November 18, 2025

"Pharma Bro' and notorious bear Martin Shkreli is shorting Olema Pharmaceuticals stock.

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results ↗

November 18, 2025

Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.

Via Stocktwits

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.